Published in Blood on January 08, 2010
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia (2010) 4.09
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A (2011) 3.07
Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol (2011) 2.69
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood (2012) 2.01
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol (2013) 1.82
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood (2014) 1.79
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood (2014) 1.53
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood (2012) 1.52
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia (2013) 1.11
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica (2010) 1.08
Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol (2013) 1.06
Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis (2011) 0.98
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med (2014) 0.98
JAK2 inhibitors: what's the true therapeutic potential? Blood Rev (2010) 0.97
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget (2011) 0.96
Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS One (2012) 0.96
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med (2013) 0.95
TET family proteins: oxidation activity, interacting molecules, and functions in diseases. Chem Rev (2015) 0.94
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med (2014) 0.93
Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat (2013) 0.92
Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. J Mol Diagn (2011) 0.92
BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer (2013) 0.88
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics (2011) 0.87
Alterations of 5-hydroxymethylcytosine in human cancers. Cancers (Basel) (2013) 0.85
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators Inflamm (2015) 0.84
Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Haematologica (2014) 0.84
Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica (2011) 0.81
Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera. Haematologica (2011) 0.81
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. Exp Hematol Oncol (2013) 0.80
Inferring the temporal order of cancer gene mutations in individual tumor samples. PLoS One (2014) 0.79
Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera. Blood (2016) 0.77
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J (2011) 0.77
JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? Am J Hematol (2012) 0.77
The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms? Cancers (Basel) (2014) 0.77
JAK2V⁶¹⁷F/TET2 mutations: does the order matter? Haematologica (2011) 0.77
Back to biology: new insights on inheritance in myeloproliferative disorders. Curr Hematol Malig Rep (2014) 0.75
The emerging insights into catalytic or non-catalytic roles of TET proteins in tumors and neural development. Oncotarget (2016) 0.75
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Manag Res (2010) 0.75
A myeloid tumor suppressor role for NOL3. J Exp Med (2017) 0.75
Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood (2011) 0.75
Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk (2016) 0.75
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? Oncologist (2016) 0.75
Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. Leuk Res Rep (2013) 0.75
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
A new hominid from the Upper Miocene of Chad, Central Africa. Nature (2002) 6.85
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood (2007) 3.52
Macrovertebrate paleontology and the Pliocene habitat of Ardipithecus ramidus. Science (2009) 3.49
Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med (2006) 3.14
Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood (2006) 2.88
Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med (2007) 2.85
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood (2006) 2.74
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood (2014) 2.72
Stem cell characteristics of amniotic epithelial cells. Stem Cells (2005) 2.66
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood (2007) 2.44
Geology and palaeontology of the Upper Miocene Toros-Menalla hominid locality, Chad. Nature (2002) 2.41
Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol (2011) 2.20
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 2.11
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood (2007) 2.10
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood (2007) 2.09
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica (2008) 2.05
Asa Issie, Aramis and the origin of Australopithecus. Nature (2006) 2.00
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood (2006) 1.89
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2006) 1.87
A new clinico-pathological classification system for mesial temporal sclerosis. Acta Neuropathol (2007) 1.77
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica (2008) 1.63
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Cesarean section due to fetal distress increases the number of stem cells in umbilical cord blood. Transfusion (2008) 1.45
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica (2008) 1.45
Hydrolytic degradation study of biodegradable polyesteramide copolymers based on epsilon-caprolactone and 11-aminoundecanoic acid. Biomaterials (2004) 1.41
The influence of age at single-event multilevel surgery on outcome in children with cerebral palsy who walk with flexed knee gait. Dev Med Child Neurol (2011) 1.40
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood (2008) 1.39
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol (2011) 1.38
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood (2003) 1.35
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica (2008) 1.33
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood (2005) 1.31
Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol (2006) 1.29
Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica (2012) 1.29
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood (2008) 1.27
The new framework for understanding placental mammal evolution. Bioessays (2009) 1.26
Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. Hepatology (2010) 1.25
Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol Pharmacol (2008) 1.24
Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood (2007) 1.22
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood (2012) 1.20
Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos (2004) 1.19
Towards a clinico-pathological classification of granule cell dispersion in human mesial temporal lobe epilepsies. Acta Neuropathol (2009) 1.17
Dental eruption in afrotherian mammals. BMC Biol (2008) 1.15
Conditional transgenic mouse models: from the basics to genome-wide sets of knockouts and current studies of tissue regeneration. Regen Med (2008) 1.14
Cell visco-elasticity measured with AFM and optical trapping at sub-micrometer deformations. PLoS One (2012) 1.12
Activating mutations in STIM1 and ORAI1 cause overlapping syndromes of tubular myopathy and congenital miosis. Proc Natl Acad Sci U S A (2014) 1.10
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood (2012) 1.07
Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics (2004) 1.06
Tracking of human cells in mice. Histochem Cell Biol (2008) 1.06
Hepatocyte transplantation: clinical experience and potential for future use. Cell Transplant (2006) 1.05
Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 Cells by estrogen and phytoestrogens. J Biol Chem (2005) 1.02
Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations. Transfus Med Hemother (2013) 1.02
Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica (2012) 1.01
Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes. Pharmacogenet Genomics (2008) 1.01
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica (2009) 0.99
Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells. Blood (2004) 0.97
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev (2005) 0.94
The evolution of drug-activated nuclear receptors: one ancestral gene diverged into two xenosensor genes in mammals. Nucl Recept (2004) 0.93
Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial. J Clin Pathol (2012) 0.93
Arabidopsis amidase 1, a member of the amidase signature family. FEBS J (2007) 0.93
Stage-specific and tissue-specific expression characteristics of differentially expressed genes during mouse spermatogenesis. Mol Reprod Dev (2004) 0.93
SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood (2011) 0.92
LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver. J Lipid Res (2005) 0.91
Subcellular localization and tissue specific expression of amidase 1 from Arabidopsis thaliana. Planta (2006) 0.91
Role of primacy of birth in HLA-identical sibling transplantation. Blood (2007) 0.91
Randomized crossover study to examine the necessity of an injection-to-meal interval in patients with type 2 diabetes and human insulin. Diabetes Care (2013) 0.91
Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci U S A (2004) 0.89
Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Ann Hematol (2010) 0.88
CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists. J Med Chem (2005) 0.88
A comparative study of four intensive care outcome prediction models in cardiac surgery patients. J Cardiothorac Surg (2011) 0.87
Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica (2014) 0.87
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter (2012) 0.86
Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood (2014) 0.86
The DEAH-box helicase RHAU is an essential gene and critical for mouse hematopoiesis. Blood (2012) 0.86